Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.
- Cantourage brings cannabis flowers of the “God Bud” variety from the grower Breathing Green Solutions from Nova Scotia, Canada to the German medical market, with other unique cultivars to follow
- For the best product quality and safety, Breathing Green grows cannabis using its proprietary PurePlantTM process, bringing unique, non-irradiated cultivars to European markets
Berlin, May 24, 2023 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01), a leading European company for the production and distribution of cannabis-based medicinal products, has announced its partnership with the Canadian cannabis cultivation company Breathing Green Solutions (hereinafter “Breathing Green”). The collaboration marks the first entry into the European market for Breathing Green, whose cannabis products have been available exclusively in the Canadian market to date. The first cannabis cultivar “God Bud” is already available in pharmacies and now offers patients a uniquely grown therapeutic option.
Breathing Green has been growing cannabis in its state-of-the-art facility in the eastern Canadian province of Nova Scotia since 2017. 50 employees grow and process cannabis flowers in seven custom designed grow chambers. With the PurePlantTM method, Breathing Green has developed its own proprietary process that ensures high-quality products come out of each grow chamber. The main features of PurePlantTM include a rigorous cannabis seed selection process, a unique grow medium, daily care for each individual plant, and customized nutrient programs for each stage of the grow cycle.
“As Nova Scotia’s first licensed producer of cannabis products and one of the top craft cannabis producers in Canada, we are very excited to now be able to offer our products to the wonderful people in Europe with the support of our expert partners, Cantourage. Our promise centres on caring for every person and plant we engage with. We are extremely proud to be able to provide a consistent and high-quality therapy option with our products.” said Savior Joseph, President of Breathing Green.
“We are pleased to add Breathing Green to our portfolio, the fourth new Canadian cannabis grower this year. We are demonstrating that we have created a very effective model with our Fast Track Access platform to bring cannabis flower and brands from all over the world to Germany and the European medical markets,” commented Philip Schetter, CEO of Cantourage.
About Breathing Green/SKOSHA
Breathing Green Solutions (BGS) is Nova Scotia’s first licensed producer of cannabis, with a head office in Halifax, Nova Scotia, and a production facility in Wentworth, Nova Scotia. BGS cannabis products are available across Canada and now in Europe. Since legalization in Canada, BGS has been a respected industry leader, holding significant market share by providing consistent, high-quality products, while ensuring full compliance with all regulations. BGS proprietary PurePlantTM growing methodology ensures that consumers around the world can always expect the highest level of product purity.
More Information: www.breathinggreen.com
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2018 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.
This announcement does not constitute a public offer or an advertisement for a public offer in the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors in the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.